Extension Study of Ataluren Treatment for Nonsense Mutation Dystrophinopathy

Clinical Trial Title

Phase 3 extension study of Ataluren (PTC124) in patients with nonsense mutation dystrophinopathy

Contact Information

Susan Rohde

Clinical Trial Protocol Description:

This study is an extension of the Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients with Nonsense Mutation Dystrophinopathy. The purpose of this study is to better understand whether Ataluren can be safely given for a long period of time.

The study will also provide additional information as to whether the actions of Ataluren can result in improved walking, activity, muscle function, muscle fragility, upper limb function, pulmonary function and health-related quality of life in boys with Duchenne muscular dystrophy.

Study Details

Contact Information

Susan Rohde

(312) 942-0079


RUSH University Medical Center

1620 W Harrison St
Chicago, IL 60612

Get Directions

Clinical Trial FAQs

Find out if a clinical trial makes sense for you.

Learn more
Learn more